GlobalData analysts have identified 18 emerging immune checkpoint targets that are currently in clinical development. When looking at four solid tumors—bladder cancer, breast cancer, cervical cancer, and colorectal cancer (CRC)—the analysis of Phase I/II to Phase III trials reveals a large majority of emerging immune checkpoint targets being explored in combination.
In the figure above, the number of clinical trials exploring immune checkpoint targets for these four indications are presented. Breast cancer and CRC show the highest number of trials, with nine and 10 trials, respectively. In these two solid tumor types, combination trials accounted for more than 85% of clinical trials.
Based on an analysis of GlobalData’s database, the Pharma Intelligence Center, most combination trials include a programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitor. GlobalData anticipates that emerging checkpoint modulators will increase the response rate of current PD-1/PD-L1 inhibitor therapies, with PD-1/PD-L1 inhibitors becoming backbone therapies for most immuno-oncology therapies.
GlobalData (2017). PharmaFocus: Visual Analysis of Immuno-Oncology Development and Opportunities, August 2017, GDHC009PFR.